UBS Seeks Legal Protection Over Credit Suisse's Nazi-Era Banking Activities 
Panama Cancels CK Hutchison Port Contracts, Grants Temporary Control to Maersk and MSC 
California Court Rejects xAI Bid to Block AI Data Transparency Law 
Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Costco Faces Class Action Lawsuit Over Tariff Refunds as Supreme Court Strikes Down Trump's IEEPA Tariffs 
USTR Launches New Section 301 Trade Investigations After Supreme Court Tariff Ruling 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Domino's Pizza UK Reports 15% Drop in Annual Profit Amid Weak Sales and Rising Costs 
U.S. Senate Greenlights AI Chatbots for Official Staff Use 
Heinz Wattie's to Close Three New Zealand Plants, Cutting 350 Jobs 
Supreme Court Blocks California Transgender Student Privacy Laws in 6-3 Decision 
PayPay IPO Expected to Price at Lower End Amid Global Market Uncertainty 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine. The agreement resolves multiple lawsuits accusing Moderna of using the companies’ LNP delivery system without authorization in its mRNA-based vaccine.
Under the terms of the settlement, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion may be paid depending on the outcome of a separate legal appeal. The deal brings closure to both U.S. and international legal actions related to the disputed vaccine technology.
Lipid nanoparticles play a critical role in mRNA vaccines, including Moderna’s COVID-19 shot. The technology acts as a protective carrier that shields fragile messenger RNA molecules and helps deliver them safely into human cells, enabling the vaccine to trigger an immune response. Genevant and Arbutus claimed ownership of key patents covering this LNP delivery system and argued that Moderna used the technology without proper licensing.
As part of the settlement, Moderna stated it will not owe royalties to Genevant or Arbutus for LNP technology in its future vaccine products. This clause removes potential financial uncertainty for the biotech company as it continues developing new vaccines, including updated COVID-19 shots and combination COVID/flu vaccines.
Investors reacted positively to the announcement. Moderna shares surged more than 10% in after-hours trading following the news. Arbutus Biopharma stock climbed approximately 11%, while Roivant Sciences, Genevant’s parent company, saw a modest gain of about 1%.
Analysts believe the settlement removes a significant legal risk for Moderna. According to Jefferies analyst Andrew Tsai, the agreement eliminates the worst-case scenario of paying double-digit royalty rates on vaccine sales. Considering Moderna has generated roughly $48 billion in global COVID-19 vaccine revenue, the settlement amount represents only a small fraction of those earnings.
The case had been scheduled to go to trial in Delaware federal court, marking what would have been the first major trial among several high-stakes patent disputes tied to COVID-19 vaccine technology. Similar lawsuits involving Pfizer and BioNTech remain ongoing, highlighting the intense competition and intellectual property battles within the rapidly evolving mRNA vaccine industry.
